Scholarlink

<p>Relapsed or refractory <i>B</i>-cell acute lymphoblastic leukemia (r/r B-ALL) remains challenging, and allogeneic hematopoietic cell transplantation (allo-HCT) is often the only curative option. Inotuzumab ozogamicin (InO) has demonstrated high remission rates in salvage settings, but concerns regarding sinusoidal obstruction syndrome (SOS) have limited its use as a bridge to transplantation. We retrospectively evaluated post-transplant outcomes following an InO-based salvage strategy in adults with r/r B-ALL who underwent allo-HCT at a single center in Japan. Eighty-one patients were included (median age, 50&#xa0;years). Twenty patients received InO before transplantation, while 61 patients previously treated with conventional chemotherapy served as a historical reference. Sequential immunotherapy was common in the InO group, with most receiving blinatumomab. The CR/CRi rate before HCT was higher in the InO group. With a median follow-up of 48&#xa0;months, the estimated 3-year overall survival and disease-free survival in the InO group were 55.3% and 56.3%, respectively. The favorable outcomes associated with InO-based therapy were more evident in Philadelphia chromosome-negative disease. SOS occurred more frequently in the InO group but was generally mild. These findings provide real-world evidence supporting the feasibility of an InO-based sequential salvage strategy as a bridge to allo-HCT in patients with r/r B-ALL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study

  • 期刊论文

  • 发表日期：

    2026年7月24日

查看全文
  • Ryo Koizumi,
  • Shinsuke Takagi,
  • Aya Nishida,
  • Mika Kuno,
  • Rikako Tabata,
  • Otoya Watanabe,
  • Kyosuke Yamaguchi,
  • Kosei Kageyama,
  • Daisuke Kaji,
  • Yuki Taya,
  • Kazuya Ishiwata,
  • Hisashi Yamamoto,
  • Akiko Masuda,
  • Yukako Koike,
  • Hideki Araoka,
  • Yuki Asano-Mori,
  • Go Yamamoto,
  • Atsushi Wake,
  • Shuichi Taniguchi,
  • Naoyuki Uchida

摘要

Relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) remains challenging, and allogeneic hematopoietic cell transplantation (allo-HCT) is often the only curative option. Inotuzumab ozogamicin (InO) has demonstrated high remission rates in salvage settings, but concerns regarding sinusoidal obstruction syndrome (SOS) have limited its use as a bridge to transplantation. We retrospectively evaluated post-transplant outcomes following an InO-based salvage strategy in adults with r/r B-ALL who underwent allo-HCT at a single center in Japan. Eighty-one patients were included (median age, 50 years). Twenty patients received InO before transplantation, while 61 patients previously treated with conventional chemotherapy served as a historical reference. Sequential immunotherapy was common in the InO group, with most receiving blinatumomab. The CR/CRi rate before HCT was higher in the InO group. With a median follow-up of 48 months, the estimated 3-year overall survival and disease-free survival in the InO group were 55.3% and 56.3%, respectively. The favorable outcomes associated with InO-based therapy were more evident in Philadelphia chromosome-negative disease. SOS occurred more frequently in the InO group but was generally mild. These findings provide real-world evidence supporting the feasibility of an InO-based sequential salvage strategy as a bridge to allo-HCT in patients with r/r B-ALL.